Mesoblast (NASDAQ:MESO) Shares Gap Down – Time to Sell?

Mesoblast Limited (NASDAQ:MESO) gapped down prior to trading on Friday . The stock had previously closed at $17.43, but opened at $16.98. Mesoblast shares last traded at $16.98, with a volume of 39,148 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Mesoblast Price Performance

The business has a 50 day simple moving average of $15.35 and a two-hundred day simple moving average of $15.36. The firm has a market capitalization of $2.21 billion, a P/E ratio of -60.71 and a beta of 2.08. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58.

Institutional Investors Weigh In On Mesoblast

A number of institutional investors and hedge funds have recently bought and sold shares of MESO. Royal Bank of Canada increased its holdings in shares of Mesoblast by 22.5% in the 1st quarter. Royal Bank of Canada now owns 26,266 shares of the company’s stock worth $404,000 after buying an additional 4,827 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Mesoblast during the 4th quarter valued at $286,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Mesoblast during the 4th quarter worth $34,000. Quadrant Capital Group LLC bought a new stake in shares of Mesoblast during the 3rd quarter worth $113,000. Finally, JPMorgan Chase & Co. grew its position in Mesoblast by 55.6% in the third quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock worth $46,000 after acquiring an additional 1,012 shares in the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.